SCHEDULE: Vanguard Group Updates Ideaya Biosciences Ownership

The Vanguard Group reports zero beneficial ownership in Ideaya Biosciences Inc. following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 1 to Schedule 13G for Ideaya Biosciences Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Ideaya Biosciences Inc. Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• As a result of the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities previously reported by these entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update, reflecting an internal organizational change at The Vanguard Group rather than a change in investment thesis for Ideaya Biosciences Inc.

Future Outlook

NA

Management Comments

• Securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors. This specific amendment reflects an internal organizational change at Vanguard rather than a strategic investment decision related to Ideaya Biosciences Inc.'s performance or industry trends. It indicates a shift in how Vanguard's various entities report their holdings, not necessarily a divestment of the underlying assets from Vanguard's broader managed funds.

Key Dates

Keywords

Ideaya Biosciences Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Ownership Change